Our Weekly Checkup takes the temperature of the medical device industry’s three largest U.S. clusters: Massachusetts, California and Minnesota.
Our indices are weighted according to market capitalization, based on the number of shares outstanding for each company from its most recent quarterly report and each Friday’s closing share price.
The Massachusetts index for the week ended July 2 closed at 5.58, up 1.6 percent compared with the prior week. Since Jan. 1, when we began tracking these companies, the index has risen 1.3 percent.
The Minnesota index for the week ended July 2 débuts at 7.11, up 17.4 percent since Jan. 1.
The California index for the week ended July 2 débuts at 4.4, up 32 percent since Jan. 1.
We also create a composite index of the three regional indices and compare it with four other indices (the S&P 500, the Dow Jones Industrial Average, the Dow’s IHI medical devices index and the NASDAQ exchange):
The Weekly Checkup also compares Monday morning’s opening share prices with their value when the markets close Friday afternoon to calculate the biggest gainers and losers.
Here are the ten firms that posted the biggest share price gains and losses during the week ended July 2:
The five biggest gainers:
- Staar Surgical Co. (CA): 18.2% (open $0.22; close $0.26)
- SeraCare Life Sciences (MA): 16.6% (open $0.45; close $0.52)
- Intraop Medical Corp. (CA): 14.3% (open $0.018; close $0.02)
- Biomerica Inc. (CA): 13.3% (open $1.05; close $1.19)
- Trimedyne Inc. (CA): 13.1% (open $2.06; close $2.33)
And the five biggest losers:
- Viking Medical Systems Inc. (MA): -80.0% (open $0.015; close $0.003)
- Biopure Corp. (MA): -38.3% (open $0.22; close $0.14)
- Argonaut Technologies Inc. (CA): -32.4% (open $0.04; close $0.03)
- Acunetx Inc. (CA): -25.0% (open $0.02; close $0.015)
- Imaging3 Inc. (CA): -22.2% (open $0.05; close $0.04)
Disclaimer: MassDevice.com’s rankings do not reflect an opinion of companies’ health, prospects or viability. They are intended to provide a snapshot of publicly traded medical device companies and in no way constitute a recommendation to buy or sell any particular security, portfolio of securities, transaction or investment strategy.